Drug Discovery World

JULY 30, 2024

Serna Bio was founded by Rabia Khan , who is also the CEO, to unlock the transcriptome as a drug discovery target. DDW’s Megan Thomas speaks to Khan about the work her team is doing to create the first map of the druggable transcriptome, which involves understanding RNA biology to discover small molecule drugs.

RNA 64

RNA Genome Genomics Protein 64

pharmaphorum

OCTOBER 12, 2022

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 104

Genome Genomics Medicine Development 104

pharmaphorum

JULY 20, 2022

Armed with a $100 million second-round financing, CAMP4 Therapeutics is preparing to start the first clinical trial of a drug targeting regulatory RNA (regRNA) molecules that can be used to fine-tune the expression of genes. ” The post CAMP4 raises $100m to take lead RNA drugs into clinic appeared first on. .

RNA 52

RNA Genetic Disease Drugs Protein 52

Drug Discovery World

NOVEMBER 7, 2022

Genomic healthcare data is critical to identify disease risk, ancestry, traits and response to medicines and aids in the development of new targeted therapies – precision medicines. In April 2003, after its launch in October 1990, the project was completed, generating the first sequence of the human genome. The origins .

Genome 98

Genome Genomics Development Genetics 98

Drug Discovery World

DECEMBER 13, 2022

Japanese researchers propose using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama muscular dystrophy. . One form of FCMD is caused by a genetic abnormality in the ‘fukutin’ (FKTN) gene. One form of FCMD is caused by a genetic abnormality in the ‘fukutin’ (FKTN) gene.

RNA 52

RNA Genetics Gene In-Vitro 52

Drug Discovery World

APRIL 17, 2024

Pooled CRISPR screens offer the ability to knock out or perturb many genes in a single experiment from several hundred to tens of thousands of targets in parallel. Genome-wide screens are becoming the standard for drug discovery to power unbiased identification of drug targets across gene regulatory networks.

Genome 52

Genome Genomics Gene Expression RNA 52

Drug Discovery World

APRIL 3, 2024

Pooled CRISPR screens offer the ability to knock out or perturb many genes in a single experiment from several hundred to tens of thousands of targets in parallel. Genome-wide screens are becoming the standard for drug discovery to power unbiased identification of drug targets across gene regulatory networks.

Genome 52

Genome Genomics Gene Expression RNA 52

pharmaphorum

OCTOBER 13, 2020

UK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen to spearhead the next stage in the company’s development into gene silencing and other areas. According to the company it will look to develop drugs that work against multiple targets that influence disease.

Gene Silencing 95

Gene Silencing Gene RNA Genome 95

Drug Discovery World

FEBRUARY 13, 2023

Dr Stephen Barat, Senior Vice President and Therapeutics Division Head at HTG Molecular Diagnostics tells DDW how transcriptomics is driving drug discovery and precision medicines. SB: Transcriptomics is the study of genomic RNA transcripts in a biological system. DDW: Could you explain the process of transcriptomics?

RNA 52

RNA Drugs Gene Expression Gene 52

Drug Discovery World

NOVEMBER 1, 2022

If further studies verify the results, this could be a new method for targeting specific cell types for a variety of disorders that could be treated with gene therapies. Two methods currently used to deliver protein-making packages into cells, ‘mini promoters’ and serotype-mediated gene expression, vary widely.

Gene Expression 52

Gene Expression Gene Packaging Packaging 52

Roots Analysis

SEPTEMBER 9, 2024

It is worth highlighting that in 2023 alone, close to 20 protein-based drugs were approved for the treatment of myriad of disease indications including oncological and metabolic disorders. This process initially involves transcription of DNA to messenger RNA (mRNA). The mRNA is then translated into to form functional proteins.

Protein 40

Protein Gene Production DNA 40

Drug Discovery World

MARCH 2, 2023

A new paper has solved the 20-year mystery of how epigenetic modifications act as traffic lights to control gene expression and could ultimately speed up the development of a new class of epigenetic cancer drugs. Epigenetics is still largely unexplored and referred to as the ‘dark matter’ of the genome.

Gene Expression 52

Gene Expression Gene DNA RNA 52

The Pharma Data

JUNE 7, 2023

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Bayer AG is joining forces with Acuitas Therapeutics, Inc., LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

Drug Discovery World

AUGUST 1, 2024

This is the latest episode of the free DDW narrated podcast, titled “Innovation drivers and opportunities for drug discovery”, which covers three articles written Volume 24 – Issue 1, Winter 2022/2023 of DDW. The post Podcast: Innovation drivers and opportunities for drug discovery appeared first on Drug Discovery World (DDW).

Gene Therapy 52

Gene Therapy Drugs Gene Medicine 52

XTalks

AUGUST 5, 2020

In recent webinars by Genuity Science, formerly known as WuXi NextCODE, experts from the biotech and pharma industries spoke about leveraging the power of single cell RNA sequencing platforms and solutions in conjunction with machine learning technologies such as AI in cell biology and disease research. The Power of Single Cell Technology.

Gene Expression 112

Gene Expression Development RNA Drugs 112

Drug Discovery World

OCTOBER 26, 2023

The technologies cover the whole range of biomolecules from genes to protein to metabolites. While we are using standard commercially available processes for genomics, we have invested massively into high-throughput and high-resolution transcriptomics, proteomics, and metabolomics methods.

Drugs 52

Drugs Protein Genome Genomics 52

Drug Discovery World

MARCH 26, 2024

For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. The post Conversations from ESMO Targeted Anticancer Therapies Congress 2024 appeared first on Drug Discovery World (DDW). We were there to present the latest findings from our research.

RNA 64

RNA In-Vivo In-Vitro DNA 64

Drug Discovery World

JUNE 22, 2023

“This is part of our long-term business strategy of leveraging exosome-mediated delivery to create and enable genetic medicines such as gene therapy and genome editors”. The post Evox Therapeutics acquires exosome AAV technology from Codiak appeared first on Drug Discovery World (DDW).

Gene Therapy 52

Gene Therapy Gene Editing Gene Drug Delivery 52

Drug Discovery World

OCTOBER 16, 2023

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. billion in funding.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

SEPTEMBER 27, 2023

Embarking on a new era of medicine The advent of genomics has ushered in the era of personalised medicine, enabling us to analyse the genetic makeup of individuals with unprecedented accuracy. Genetic variations inherited from our parents shape our response to drugs, disease susceptibility, physiology and metabolism.

DNA 115

DNA Genetics Gene Medicine 115

Drug Discovery World

APRIL 17, 2024

DDW’s Diana Spencer speaks to Josh Mandel-Brehm , CEO of Massachusetts-based biotech CAMP4, to understand the role regulatory RNAs play in gene expression and how the founders overcame the challenge of launching a business based on brand new science. What are the challenges of drug discovery in this area? How do they work?

Gene Expression 59

Gene Expression Gene Genetic Disease RNA 59

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

Drug Discovery World

DECEMBER 21, 2023

DDW’s top 10 most popular articles for 2023 reflect the key subjects in drug discovery and development. In a record year for gene therapy approvals, it isn’t surprising that cell & gene therapy (CGT) has been a hot topic. This well-read article featured in the DDW Winter 22/23 issue’s Cell & Gene Therapy Guide.

Gene Therapy 59

Gene Therapy Gene Antibody FDA Approval 59

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Moreover, the manual protocols require extensive manipulation, costly reagents and long duration of skilled genomic library production. Nanoparticles Contract Manufacturing.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

pharmaphorum

AUGUST 10, 2021

Oxford University and UK clinical artificial intelligence (AI) company Sensyne Health will partner on a project to find new drug targets for people with hard-to-treat asthma. Dr Timothy Hinks. According to Hinks, “we still don’t understand the causes of asthma, because in the past the scientific tools just didn’t exist.

Gene Sequencing 116

Gene Sequencing Bioinformatics Gene Genome 116

Drug Discovery World

OCTOBER 19, 2022

Yapan Bio has expanded its capabilities with a new process development facility at Genome Valley, Hyderabad, India, which has enhanced its ability to support end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids. .

Development 52

Development Gene Therapy DNA RNA 52

Pharmaceutical Technology

DECEMBER 9, 2022

In regards to the latter, notable examples include the acquisition of Cergentis, a genomics-focused biotechnology company based in the Netherlands. The deal allows the company to provide proprietary technology and knowledge steeped in fast-evolving genomic techniques that support effective decision-making and R&D program design.

Development 130

Development Production Manufacturing Vaccination 130

Pharmaceutical Technology

DECEMBER 14, 2022

The alliance will merge the PRISM oligonucleotide platform of Wave and the capabilities of GSK in genetics and genomics. An RNA editing therapy, WVE-006, could act on AATD’s liver and lung manifestations. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. By Cytiva Thematic.

Life Science 162

Life Science Development Gene Therapy Genetics 162

XTalks

NOVEMBER 30, 2023

In 2022, the US Food and Drug Administration (FDA) granted approval to the medication Sunlenca (lenacapavir) for adults living with multi-drug resistant HIV-1 infection. Developed by Gilead, Sunlenca is the first drug in a novel class known as capsid inhibitors to receive FDA approval for treating HIV-1.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Delveinsight

SEPTEMBER 14, 2021

ADARx bags USD 75 Million to advance its RNA tech pipeline. ADARx Pharmaceuticals, a biotechnology company developing RNA targeting therapeutics , announced the completion of a USD 75 million Series B financing to progress its drug development pipeline. Vor Biopharma’s AML drug secures Fast Track Designation.

RNA 67

RNA Clinical Trials Clinical Trials Drugs 67

XTalks

DECEMBER 1, 2021

To ensure the new tests can identify Omicron based on its mutations, the companies assessed their tests against sequences in public databases of genomic data, such as GISAID and GenBank. Cue is also currently working with Google Cloud and genomics company Helix to study variants and share mutation sequencing data.

Gene 105

Gene Genome Genomics Genetics 105

Drug Discovery World

OCTOBER 4, 2022

DDW Editor Reece Armstrong explores some of the trends that will be featured in sessions throughout ELRIG Drug Discovery 2022 and the news behind them. Cell and gene therapies. There’s no question that cell and gene therapies have emerged as some of the most promising and innovative medicines on the market. .

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

Drug Discovery World

AUGUST 16, 2023

A new study has shed light on the genetic messages encoded by genes within ‘triple negative’ breast cancers (TNBC), and shows they could predict response to chemotherapy. Although immune features remained relatively stable, RNA-based features related to DNA damage repair pathways changed significantly.

Genetics 52

Genetics Gene Hormones RNA 52

Roots Analysis

FEBRUARY 23, 2022

Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and third generation sequencing technologies. Currently, close to 60 industry players are actively offering NGS kits for preparing DNA / RNA libraries. Players Engaged in the Domain.

Genetics 52

Genetics DNA RNA Reagent 52

Drug Discovery World

SEPTEMBER 14, 2023

This includes Aztreonam-avibactam (PF-06947387), Danuglipron (PF-06882961), Elranatamab (PF-06863135), Fidanacogene elaparvovec (Haemophilia B Gene Therapy), GBS6 (PF-06760805, Group B Streptococcus Vaccine), and Marstacimab (PF-06741086).

Drugs 59

Drugs Vaccination Vaccine Medicine 59

The Pharma Data

DECEMBER 13, 2020

which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., Zhang has around 20 years of experience in research and drug development in both industry and academia in the US. 14, 2020 10:00 UTC.

Business Development 40

Business Development Development Gene Editing In-Vivo 40

Drug Discovery World

MAY 23, 2024

Reece Armstrong speaks to Samuel Deutsch , Chief Scientific Officer of Nutcracker Therapeutics about the RNA landscape and how it can benefit the development of immunotherapies. RA: What role does RNA play in the development of effective immunotherapies? SD: This is definitely a challenge.

RNA 59

RNA Protein Manufacturing Production 59